PD26-11 ANALYSIS OF INCIDENTAL PROSTATE CARCINOMA IN 1,106 PATIENTS UNDERGOING BPH SURGERY IN A DEVELOPING COUNTRY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology I1 Apr 2014PD26-11 ANALYSIS OF INCIDENTAL PROSTATE CARCINOMA IN 1,106 PATIENTS UNDERGOING BPH SURGERY IN A DEVELOPING COUNTRY Luiz Henrique Araujo, Gabriel Carvalho dos Anjos, Marcelo Bigarella, Sabrina Thalita dos Reis, Miguel Srougi, and Alberto Azoubel Antunes Luiz Henrique AraujoLuiz Henrique Araujo More articles by this author , Gabriel Carvalho dos AnjosGabriel Carvalho dos Anjos More articles by this author , Marcelo BigarellaMarcelo Bigarella More articles by this author , Sabrina Thalita dos ReisSabrina Thalita dos Reis More articles by this author , Miguel SrougiMiguel Srougi More articles by this author , and Alberto Azoubel AntunesAlberto Azoubel Antunes More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2098AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The widespread use of screening for prostate cancer (PCa) resulted in a decreased incidence of incidental carcinoma of the prostate (iPCa) in patients who undergo surgery for benign prostatic hyperplasia (BPH). With the increasing use of laser vaporization techniques in developing countries, some concerns have been raised regarding the actual incidence of iPCa, since these technics do not result in tissue samples for pathological analysis. The aim of the study is to evaluate the current incidence of iPCa in patients submitted to BPH surgery and analyze the characteristics of these patients. METHODS We performed a retrospective analysis of 1,899 patients of whom 1,106 underwent surgery for BPH between 2007 and 2011 at a single institution. The types of BPH surgery were transurethral resection of prostate (TURP) or open prostatectomy (OP). All patients underwent a preoperative screening for PCa with prostate specific antigen (PSA), digital rectal examination and prostate biopsy if necessary, according AUA guidelines. Patients diagnosed with PCa before surgery were excluded from the sample. Patients with iPCa were evaluated for age, preoperative PSA (<10, 10-20 or >20), type of surgery (TURP or OP); resected prostate weight; percent of tumor in the surgical specimen (≤ 5 %, 5-10% or >10%) and Gleason score (<7 or ≥ 7). RESULTS Of 1,106 patients, 51 (4.6%) had iPCa. The mean age of patients was 70.6 (54-90) years, mean preoperative PSA was 9.5 (1.2-37.9) ng/ml. Of these patients, 32 (65%) had PSA <10 ng/ml, 10 (20.4%) had PSA between 10-20 ng/ml and 7(14.6%) had PSA> 20 ng/ml. 31 (63.2%) patients had undergone TURP and 18 OP (36.8%). The average weight of resected prostate was 33.2 g. Regarding percent of tumor in the surgical specimen, 34 (68%) patients had ≤5%; 7(14%) were between 5- 10% and 9 (18%) had > 10% tumor in the specimen. 42 (84%) of patients with iPCa had Gleason <7, while 8 (16%) had Gleason ≥7. CONCLUSIONS This is the largest series to date analyzing this issue in a developing country. The actual incidence of iPCa is 4.6%. Patients who are candidates for laser vaporization of the prostate should be informed about this risk. Furthermore, 16% of these patients have Gleason score ≥ 7 and around 20% have > 10% of tumor in the surgical specimen, which may compromise the prognosis of these patients. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e763 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Luiz Henrique Araujo More articles by this author Gabriel Carvalho dos Anjos More articles by this author Marcelo Bigarella More articles by this author Sabrina Thalita dos Reis More articles by this author Miguel Srougi More articles by this author Alberto Azoubel Antunes More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...